Breakthrough in immunotherapy against infections
Reboot Sciences is developing a new therapy to prevent secondary infections in trauma and ICU patients. Goal: to save lives and improve care.
Reboot 001
Reboot Sciences is developing Reboot 001, a therapy that prevents secondary infections in trauma and ICU patients and saves lives. As a startup, we focus on early development and seek collaboration later on to bring the product to market.
Targeted immune modulation
In animal studies, Reboot 001 showed promising results. The drug helped mice survive a severe infection.
Life-saving prevention
What makes Reboot 001 special is that it gives the immune system a boost at precisely the moment when the body is struggling the most.
Advanced biotechnology
The first version arose from a striking discovery: people with a tropical parasite are less susceptible to sepsis. This parasite produces a protein that powerfully activates the immune system.
Why this is important
Based on this, we have further developed Reboot 001. It acts as a powerful boost to the innate immune system, enabling the body to respond more effectively to severe infections.